1-8. (canceled)
9. A cryogenic fluid tank, comprising an outer envelope and an inner envelope, the interspace between the envelopes being occupied by a multilayer insulating structure, wherein the inner envelope is supported on a pivot point (A) formed by a support structure secured to the outer envelope and extending inside the latter, the pivot point being situated above the center of gravity (G) of the inner envelope.
10. The tank of claim 9, wherein the support structure extends inside a hollow volume of the inner envelope.
11. The tank of claim 10, wherein it has lines for the transfer of fluids andor electrical signals communicating with the inside of the inner envelope and extending outwards into the support structure.
12. The tank of claim 9, wherein the inner envelope has a generally cylindrical configuration with a longitudinal axis.
13. The tank of claim 12, wherein the support structure is orthogonal to the longitudinal axis.
14. The tank of claim 10, wherein the hollow volume is formed by a bell-shaped structure extending transversely centrally inside the inner envelope.
15. The tank of claim 9, wherein the pivot point is formed by a ball joint positioned between the walls of the hollow volume and the support structure.
16. A use of the tank of claim 9 in a motor vehicle.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of synthesizing stereochemically defined iminocyclitol comprising
replacing an intraring oxygen in a cyclic sugar by an intraring imine to form an iminocyclitol, wherein said iminocyclitol has a defined stereochemical configuration different from a stereochemical configuration of the cyclic sugar.
2. The method of claim 1, wherein said replacing an intraring oxygen comprises reacting the cyclic sugar with a reagent comprising NH3.
3. The method of claim 1, wherein the cyclic sugar is an aldopentose in a 4-deoxy 1,4 furanose form, an aldohexose in a 4-deoxy 1,4 furanose form or an aldohexose in a 2,5-dideoxy pyranose form and wherein the cyclic sugar is substituted at the C1 position by R1, wherein R1 is an alkyl group comprising from 1 to 20 carbon atoms.
4. The method of claim 3, further comprising reacting a protected lactone compound with a Grignard reagent R1MgX to form the cyclic sugar, wherein a stereochemical configuration of the protected lactone compound is the same as the stereochemical configuration of the cyclic sugar.
5. The method of claim 4, further comprising protecting hydroxyl groups of an unprotected lactone compound to form the protected lactone compound, wherein a stereochemical configuration of the unprotected lactone compound is the same as the stereochemical configuration of the protected lactone compound.
6. The method of claim 5, wherein the unprotected lactone compound is an aldopentose or an aldohexose in a 4-deoxy 1,4 furanose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C5 atom of the unprotected lactone compound with methanesulfonate, tosylate or triflate protective group.
7. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 4-deoxy 1,4 furanose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C6 atom of the unprotected lactone compound with a trityl or t-butyldimethylsiloxy group.
8. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 2,5-dideoxy pyranose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C6 atom of the unprotected lactone compound with a methanesulfonate protective group.
9. The method of claim 5, wherein the unprotected lactone compound an aldopentose or an aldohexose in a 4-deoxy 1,4 furanose and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C2 atom and a hydroxyl group on the C3 atom by an isopropyldene.
10. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 2,5-dideoxy pyranose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C3 atom and a hydroxyl group on the C4 atom by an isopropyldene.
11. The method of claim 5, wherein the unprotected lactone compound is an aldopentose or an aldohexose in a 4-deoxy 1,4 furanose, wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C2 atom and a hydroxyl group on the C3 atom by benzyl, t-butyldimethylsiloxy or triphenyl groups.
12. The method of claim 5, wherein the unprotected lactone compound is an aldohexose in a 2,5-dideoxy pyranose form and wherein said protecting hydroxyl groups comprises protecting a hydroxyl group on the C3 atom and a hydroxyl group on the C4 atom by benzyl, t-butyldimethylsiloxy or triphenyl groups.
13. The method of claim 1, further comprising hydrogenating the iminocyclitol to form a hydrogenated iminocyclitol, wherein a stereochemical configuration of the hydrogenated iminocyclitol is the same as the stereochemical configuration of the iminocyclitol.
14. The method of claim 13, wherein hydrogenating the iminocyclitol is carried out in the presence of a catalyst.
15. The method of claim 14, wherein the catalyst comprises PdC and acetic acid.
16. The method of claim 13, further comprising aminating the hydrogenated iminocyclitol to form a N-alkyl-C-alkyl iminocyclitol, wherein a stereochemical configuration of the N-alkyl-C-alkyl iminocyclitol is the same as the stereochemical configuration of the hydrogenated iminocyclitol.
17. The method of claim 16, wherein aminating the hydrogenated iminocyclitol comprises reacting the hydrogenated iminocyclitol with an aldehyde R2CHO and the N atom of the N-alkyl-C-alkyl has a substituent group R2CH2, and wherein R2 is hydrogen or an alkyl group comprising from 1 to 20 carbon atoms, and deprotecting C2 and C3 hydroxyl groups of the N-alkyl-C-alkyl iminocyclitol.
18. The method of claim 16, wherein hydrogenating the iminocyclitol, reacting the hydrogenated iminocyclitol with an aldehyde and deprotecting C2 and C3 hydroxyl groups of the N-alkyl-C-alkyl iminocyclitol are carried out simultaneously.
19. A stereochemically defined iminocyclitol compound or a salt thereof, wherein said compound having a formula selected from the group consisting of
R1 is an alkyl group comprising from 1 to 20 carbon atoms,
R2 is hydrogen or an alkyl group comprising from 1 to 20 carbon atoms,
R3 is hydrogen or an alkyl group comprising from 1 to 20 carbon atoms,
R4 is hydrogen or a first protecting group,
R5 is hydrogen or a second protecting group,
R6 is hydrogen or a third protecting group selected from the group consisting of methanesulfonate, tosylate and triflate;
R7 is hydrogen or a fourth protective group selected from the group consisting of t-butyldimethylsiloxy and tretyl radicals, wherein the first and the second protective form together isopropylidene or cyclohexylidene or are identical protective groups selected from the group consisting of benzyl, t-butyldimethylsiloxy radical and triphenylmethyl.
20. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
and wherein R1, R2 and R6 are as defined in claim 19.
21. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula is
and wherein R1, R2 and R6 are as defined in claim 19.
22. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
23. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
24. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
25. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
26. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
27. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
28. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2 and R6 are as defined in claim 19.
29. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2, R6 and R7 are as defined in claim 19 and wherein R4 and R5 form together isopropylidene or are hydrogen atoms.
30. The compound of claim 19 or a salt thereof, wherein a stereochemical configuration of the formula of the compound is
wherein R1, R2, R6 and R7 are as defined in claim 19 and wherein R4 and R5 form together isopropylidene or are hydrogen atoms.
31. An inhibitor of sugar chain related enzymes comprising the compound of claim 19.
32. A medicine comprising the compound of claim 19.
33. The medicine of claim 32, wherein said medicine is an antiviral agent, an anticancer agent or an immunostimulant agent.
34. A method of treating a viral infection comprising contacting a cell infected with a virus causing the infection with the compound of claim 19.
35. The method of claim 34, wherein the virus is a hepatitis virus.
36. The method of claim 35, wherein the hepatitis virus is a hepatitis B virus.
37. The method of claim 35, wherein the hepatitis virus is a hepatitis C virus.
38. The method of claim 35, wherein the virus is a BVDV virus.
39. The method of claim 34, wherein the contacting the cell comprises administering the compound to a subject containing the cell.
40. The method of claim 39; wherein the subject is a mammal.
41. The method of claim 40, wherein the mammal is a human.